Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Larger DA diameter was significantly related to this low systemic blood flow in the early hours after birth. [13] By the time the PDA became clinically apparent (mean 72 hours), the infants were ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

A groundbreaking advancement in paediatric heart care is transforming how doctors treat one of the most common and ...

The Bedside Cardiac Procedure, Once Requiring Transport of Fragile patients to a Catheterization Lab, is now performed ...

About The Study: In extremely preterm infants with a protocol-defined patent ductus arteriosus, death or bronchopulmonary dysplasia did not differ between the expectant management group and the active ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

In light of the variability in early ductal constriction and the early hemodynamic impact of an unconstricted DA, it may be that closure after the first 24 hours of life may be too late. Further, the ...